Evidence implicating prolactin (PRL) and growth hormone (GH) in the regulation of the immune system has been reviewed. Hypophysectomized animals have deficiencies in both cell-mediated and humoral immunological functions and either PRL or GH corrects these deficiencies. Animals administered bromocryptine, a drug that specifically blocks PRL release, have impaired immune responses similar to hypophysectomized animals, and again both PRL and GH correct these deficiencies. Genetically dwarf animals, which lack both PRL and GH, are also immunocompromised, and once again PRL and GH can correct the deficiencies. In dwarf animals, however, fewer studies have examined PRL actions. In growth-deficient children, immune function is not dramatically altered and basal secretion of GH has been reported. Very few clinical studies have examined whether PRL secretion is also deficient, and this may explain why a clear loss in immune function is not evident in growth-deficient children. In a number of species, including man, both PRL and GH stimulate thymic function and increase the secretion of thymulin, a thymic hormone. No studies, however, have reported on the effects of PRL and GH on other thymic hormones. A number of studies have reported in vitro effects of PRL and GH on cells involved with immunity, and the presence of high-affinity PRL and GH receptors have been observed on a number of these cells. The action of GH on the proliferative response of cells involved with immunity in vitro appears to be mediated by the production of insulin-like growth factor I. The effect of PRL on insulin-like growth factor I production by these cells has not been examined. One of the most consistent findings from in vitro studies is that prolactin antisera blocked a number of immune reactions. This led to the discovery that cells involved with immunity appear capable of producing PRL and GH, but the physiological significance of these observations have not been explored. There is a great need to identify the cell types responding to PRL and GH and this should be a goal of future investigations. There is also a need for investigators to be aware that both PRL and GH are involved in the regulation of the immune system and to design experiments to elucidate where each functions in the maturation cascade of cells involved with immunity. From the evidence available, it is apparent that PRL and GH have an important function in the immune system and future investigations should be directed toward elucidating their site(s) of action.
Central nervous system regions were examined in long term ovariectomized rats to determine if they are involved in the estrogen-induced afternoon surge in plasma PRL. Adult female rats were ovariectomized 2-3 weeks before bilateral radiofrequency or electrolytic lesions of the brain were placed on day 0. In short term lesion studies, catheterizations and sc injections of polyestradiol phosphate (PEP) were done after the lesion was made; blood sampling was performed on day 2, 3, 4, or 6. In long term lesion studies, the catheterization and PEP injection were done on day 21; blood was collected on day 28. In short term experiments, extensive lesions in the medial preoptic area/suprachiasmatic nuclei (MPO/SCN) completely blocked the PEP-induced afternoon PRL surges sampled on days 2, 3, 4, and 6, while bilateral lesions in the corticomedial amygdala (CMA) had no effect. Discrete bilateral lesions of either MPO or SCN eliminated the afternoon PRL surge on day 6. Discrete, yet complete, lesions of the ventromedial nuclei of the hypothalamus also blocked the PRL surge; however, lesions in the dorsomedial nuclei of the hypothalamus increased, the magnitude of the afternoon PRL surge. In long term studies, lesions of the CMA delayed and attenuated the PEP-induced PRL surge, and lesions of the stria terminalis for 4 weeks had a similar effect. As in the short term lesion studies, long term lesions of the MPO/SCN eliminated the daily rhythm of PRL secretion, although small sporadic rises in plasma PRL levels could be observed throughout the sampling period. It can be concluded that structural integrity of the MPO/SCN and ventromedial hypothalamic nuclei is essential for the estrogen-induced afternoon PRL surge; destruction of the dorsomedial hypothalamic nuclei can increase the magnitude of the afternoon PRL surge; and the CMA is not essential for induction of the PRL surge even though removing its neural input to the hypothalamus for an extended period can delay the onset of and suppress the magnitude of hormone release.
Levels of plasma prolactin were estimated in ovariectomized, estrogen-treated rats following the systemic administration of several neural blocking and stimulating drugs. Phenoxybenzamine, an alpha-adrenergic blocker, at high doses, increased plasma prolactin. Phenotlamine, another alpha-adrenergic blocker, and propranolol, a beta-adrenergic blocker, also increased prolactin but the responses were small and transient. Clonidine, an alpha-adrenergic stimulating drug, elevated prolactin levels whereas the beta-adrenergic stimulator isoproterenol had no effect. Dopaminergic blockade by pimozide increased levels of prolactin while stimulation of dopamine receptors by apomorphine decreased prolactin release. Atropine (a muscarinic chilinergic blocker), arecoline (a muscarinic stimulator) and nicotine (a nicotinic cholinergic stimulating drug) did not affect basal prolactin levels. Mecamylamine (a nicotinic blocker) produced a small transient elevation in plasma prolactin. Methiothepin, an alleged serotoninergic blocker, markedly increased prolactin secretion, as did serotonin. The data suggested the involvement of several neurotransmitters in the control of basal secretion of prolactin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.